Last Updated: Wednesday, January 16, 2013
Principal Investigator: Jeremy M. Veenstra-VanderWeele, M.D.
Other researchers: Cassandra Newsom, PhD and Kevin Sanders, MD
Vanderbilt University has studied a new medication to help with agression, irritability and moodiness in children and teens with Fragile X. Our results indicated improvement in social withdrawal. The purpose of this study is to find out if STX209 (R-Baclofen) is effective in treating social withdrawal in people with Fragile X. This randomized placebo-controlled study will help us determine whether the effects we saw before can be seen in a new group of people.
The study lasts 12 weeks. It involves 7 visits to Vanderbilt University in Nashville, TN. We need you to give blood at several of those visits.
There is no cost to you for being in this research study. You will get evaluations from a psychologist and psychiatrist during your study visits, and study medications at no cost.
Sponsored by Seaside Therapeutics.
Read more about Fragile X research at Vanderbilt by clicking here.
Adolescents and young adults (12-25 years old) with Fragile X syndrome
$25 per visit in a check mailed to your home
7 visits to Vanderbilt University in Nashville, TN.
Adults 18-45 with Fragile X syndromeCompensation: Yes
Adolescents (12-17 years old) with Fragile X syndromeCompensation: Yes
Children with a confirmed diagnosis of Fragile X between 3 and 11 years.Compensation: Yes
Adults age 16– 50 with Fragile X for a study using an investigational drug.Compensation: Yes
We are looking for children ages 6-12 with Autism, Asperger’s Syndrome, or PPD-NOS.Compensation: Yes
Visit this investigator's people page to list all of their studies together.